Keros Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Keros Therapeutics achieved net income in 2025 driven by a Takeda licensing deal, while progressing lead candidates rinvatercept and elritercept, and executing a significant capital return program.
NASDAQ
Keros Therapeutics reports its 2024 financial results, highlighting key clinical program advancements and a new licensing agreement with Takeda Pharmaceuticals.
NASDAQ
Keros Therapeutics' 10-K filing outlines the details of its common stock, voting rights, dividend policies, and anti-takeover provisions, alongside updates on clinical trials and financial status.